These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11092268)

  • 1. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist.
    Igarashi M; Okuda T; Oh-i T; Koga M
    J Dermatol; 2000 Oct; 27(10):643-50. PubMed ID: 11092268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B; Bianchi E; Agostoni A
    Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis.
    Kato S; Kishiro I; Machida M; Fuse D; Yoshida T; Kaneko N
    J Int Med Res; 2000; 28(6):258-68. PubMed ID: 11191719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon.
    Coffman JD; Cohen RA
    Clin Sci (Lond); 1994 Mar; 86(3):269-73. PubMed ID: 8156737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma 6 keto PGE1 alpha concentration in Raynaud's phenomenon.
    Kinney EL; Demers LM
    Prostaglandins Med; 1981 Nov; 7(5):389-93. PubMed ID: 6895673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does prevalence of migraine and Raynaud's phenomenon also increase in Korean patients with proven variant angina?
    Koh KK; Kim SH; Lee KH; Kwon KS; Kim EJ; Baik SH; Cho SK; Kim SS; Park CO; Chung JK
    Int J Cardiol; 1995 Aug; 51(1):37-46. PubMed ID: 8522395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal platelet aggregation in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B
    J Clin Pathol; 1989 Jul; 42(7):716-8. PubMed ID: 2760232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the Raynaud's phenomenon with piracetam.
    Moriau M; Lavenne-Pardonge E; Crasborn L; von Frenckell R; Col-Debeys C
    Arzneimittelforschung; 1993 May; 43(5):526-35. PubMed ID: 8328997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.